A353 predictive value of 52% (95%CI, 37%-68%) and a negative predictive value of 97% (95%CI, 83%-100%). Results at 6-months follow-up were similar. Total mean medical costs per patient for PWU and CWU were € 11,302 and € 11, and € 12,670 and € 13,, respectively. The incremental costs were in favor of the PWU patients (€ 482 (6-months), € 1,105 (12-months)). Sensitivity analyses showed that the most influential parameters were hospitalization, treatment-related operations and cost of PET. ConClusions: The introduction of 18F-FDG PET in the diagnostic trajectory of laryngeal cancer patients with suspected recurrence after radiotherapy is feasible, safe and favorable from clinical and economic perspectives.
objeCtives: The Sanger sequencing method has been considered the gold standard DNA sequencing technique for approximately 30 years; however, it is now challenged by next generation sequencing (NGS) . The aim of this study was to assess the cost entailed by Sanger DNA sequencing when it is used for somatic genetics. Methods: The cost assessment was based on a multicenter study using a micro-costing approach. We observed Sanger sequencing sessions that started with the DNA sample and finished with the bio-informatics evaluation. The hospitals' point of view was retained. Only direct costs were taken into account. Uncertainty was captured for each stage using a deterministic sensitivity analysis. All costs are expressed in Euros 2015. Results: Five sequencing sessions were investigated in four French cancer centers from February 2015 to May 2015. In total, DNA samples from 87 patients with 658 exons were sequenced with a mean duration of 1.815 minutes per session. The mean total cost of sequencing was € 1,891 (SD: 1,460). The cost per patient was € 108 (SD: 30.36) and cost per exon was € 18 (SD: 5.52). The personnel (52% of total costs, SD: 0.03) and consumable (43% of total costs, SD: 0.03) costs represented the highest cost drivers. The bio-informatics analysis and DNA extraction were the costliest stages of the sequencing process (28 and 26%, respectively). Total costs were highly correlated with the number of patients and exons. The marginal costs were € 112 and € 12 per additional patient and exon, respectively. ConClusions: Our findings demonstrate the moderate costs of Sanger sequencing. These results can be used for further economic analyses comparing Sanger sequencing methods with other DNA sequencing methods such as NGS.
PMD54
The econoMics of criTical care DiagnosTics: The case of ProcalciTonin-guiDeD care in TreaTMenT of acuTe resPiraTory infecTion in The u.s Schneider JE 1 , Schuetz P 2 , Lacey M 1 , Stojanovic I 1 , Scheibling CM 1 1 Avalon Health Economics, Morristown, NJ, USA, 2 University of Basel, Basel, Switzerland objeCtives: Recent advances in novel diagnostics have led to some concerns on the part of purchasers as to whether the diagnostics add value or simply add cost. In this study we explore these concerns, using as an example the case of antibiotic stewardship protocols based on procalcitonin levels. The objective is to assess the economic impact of adopting procalcitonin testing among patients with suspected acute respiratory tract infection (ARI) from the perspective of a typical U.S. integrated delivery network (IDN) with a 1,000,000 member catchment area or enrollment. Methods: To conduct an economic evaluation of procalcitonin testing versus usual care we built a cost-impact model based on patient-level meta-analysis data of randomized trials. The meta-analytic data was adapted to the U.S. setting in reducing antibiotic exposure in adult ICU patients with sepsis, compared to current practice in The Netherlands (NL), Germany and the UK. The reduction in antibiotic days as achieved by a PCT-algorithm is important given the rise in antibiotic resistance (ABR). Prolonged antibiotic duration affects the incidence of ABR and C. difficile infections (CDI), in this population amounting to 4.7% and 4.6% per hospital episode, respectively. We estimated the additional indirect cost savings of PCTtesting by considering excess length of stay (LOS) due to ABR and CDI. Methods: Health economic consequences of a PCT-algorithm vs. current practice are analysed from a societal perspective using a decision tree. Input data were obtained from a systematic literature review and country-specific cost data sources. Effects of reduced duration of antibiotic therapy on ABR and CDI incidence and expected cost savings of a PCT-strategy were estimated for NL. Cost-effectiveness is expressed as incremental costs per antibiotic day avoided. Results: Excess LOS due to ABR and CDI is 4.6 days and 0.9 days per patient respectively. Shorter duration of antibiotic therapy, as achieved by a PCT-algorithm, decreases ABR and CDI incidence to 4.5% and 3.9%, respectively. Including ABR and CDI costs in the analyses increases per-patient costs in both strategies, but less so for the PCT-algorithm. As a result, incremental cost savings of a PCT-algorithm compared to current practice increase with € 290 (from € 3,503 to € 3,793 per patient) when considering ABR and CDI. This further strengthens the dominance of the PCT-algorithm (ICER: -€ 2,231 per antibiotic day avoided). ConClusions: By reducing ABR and CDI incidence, a PCT-algorithm is expected to generate substantial indirect cost savings beyond direct health and economic impacts in ICU patients with sepsis.
PMD50 clinical-econoMic MoDeling analysis of huMan PaPilloMavirus (hPv) co-TesTing WiTh genoTyPing versus PriMary hPv TesTing for cervical cancer screening
Felix JC 1 , Lacey MJ 2 , Miller JD 2 , Lenhart GM 2 , Kulkarni R 2 1 Keck School of Medicine, University of Southern California, Los Angeles, CA, USA, 2 Truven Health Analytics, Cambridge, MA, USA objeCtives: Consensus US cervical cancer screening guidelines recommend use of co-testing (combination Pap plus HPV testing) for women aged 30-65 years. Though not currently recommended by US guidelines, an HPV test was approved by the FDA in 2014 for primary cervical cancer screening in women 25 years and older. In this study, we perform clinical-economic comparisons of co-testing with genotyping (Co-test GT) versus primary HPV with genotyping and reflex cytology (HPV GT) for cervical cancer screening. Methods: A health state transition (Markov) model with one-year cycling was developed using epidemiologic, clinical, and economic data from healthcare databases and published literature. A cohort of one million women receiving triennial cervical cancer screening was simulated from ages 30-70 years. Screening strategies compared HPV GT to Co-test GT. Outcomes included total and incremental differences in costs, invasive cervical cancer (ICC) cases, ICC deaths, and quality-adjusted life years (QALYs) for cost-effectiveness calculations. Comprehensive sensitivity analyses were performed. Results: In a simulation cohort of one-million 30-year-old women modeled up to age 70, the model predicted as many as 2,141 ICC cases and 2,040 ICC deaths could be prevented with Co-test GT versus HPV GT. Co-test GT demonstrated a greater number of lifetime QALYs (22,334) and yielded $36.1 million in savings compared with HPV GT, thereby conferring greater effectiveness at lower cost. Applying this model to the cross-section of 78.9 million US women aged 30-70 years predicts nearly 150,000 ICC cases and more than 100,000 ICC deaths could be avoided with Co-test GT versus HPV GT, representing cost savings of approximately $4 billion over 40 years. ConClusions: Model results demonstrate that co-testing with genotyping provides superior clinical and economic outcomes when compared to primary HPV testing with genotyping and reflex cytology. These findings are important to US healthcare payers and women's health policy advocates seeking cost-effective cervical cancer screening technologies. objeCtives: The aim of this study was to investigate the potential benefits and cost consequences of introducing 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET) in the diagnostic work-up of patients with suspected recurrent laryngeal cancer after radiotherapy. Methods: REcurrent LAryngeal carcinoma PET Study (RELAPS), a prospective multicenter randomized controlled trial, recruited 150 patients from eight head and neck cancer centers in the Netherlands and one center in Belgium. Two diagnostic algorithms were compared to the reference standard: (1) Conventional work-up (CWU); direct laryngoscopy with biopsy under general anesthesia, and (2)18F-FDG PET work-up (PWU) followed by laryngoscopy; only for positive or equivocal findings. Standard reference comprised histopathology and clinical follow-up of 6-and 12-months, respectively. Diagnostic performance of 18F-FDG PET and indication of unnecessary operations were efficacy measures. Dutch healthcare perspective was used to obtain input parameters from hospital databases, patient records, literature and publicly available sources. Costs were expressed in 2014 Euros. Sensitivity analysis was performed. Results: Indication for direct laryngoscopy was classified unnecessary in 49 CWU patients (68%, 95%CI: 56-79) compared to 21 PWU patients (28%, 95%CI: 18-40) (p< 0.0001). The absolute difference between groups at 12-months was 40%. 18F-FDG PET had a sensitivity of 96% (95%CI, 78%-100%), specificity of 59% (95%CI, 44%-72%), a positive remaining six program designs can all be considered cost effective depending on what the health-care decision makers are ready to pay for gaining a quality-adjusted life-year. ConClusions: Based on the results of the simulated screening programs, initiation of screening at the age of 75 with repeated screening at 80 years was found to be the most cost-effective design of a screening program for unknown AF when a QALY is considered to be worth approximately € 50,000.
PMD51 recurrenT laryngeal carcinoMa PeT sTuDy (relaPs): cosT analysis of 18f-fDg PeT in PaTienTs WiTh susPecTeD recurrenT laryngeal cancer Previously TreaTeD WiTh raDioTheraPy

PMD58 higher accuracy of BlooD glucose MoniToring sysTeMs in TyPe 2 insulin TreaTeD DiaBeTic PaTienTs in sPain: clinical anD econoMic iMPacT
Khan-Miron A Universitat Pompeu Fabra, Barcelona, Spain objeCtives: Accuracy standards of blood glucose monitoring systems have been recently revised. The revised standard, ISO 15197:2013, tightens the range of results considered accurate from a 20% deviation from the reference value to a 15%. The objective of this analysis is to evaluate the economic value of accuracy differences between ISO compliant and non ISO compliant meters in Spain, using a modelling approach. Methods: Clinical and economic outcomes were simulated over a 20-years time horizon by means of a Markov model. 4 health states were considered, including no event, non-fatal hypoglycemia, fatal hypoglycemia and death due to other causes. Model inputs were derived from published sources. Inputs included Spanish Type 2 diabetes mellitus (T2DM) insulin-treated population size, risk of severe hypoglycemic event (SHE) due to meter error, cost per SHE and rates of death due to SHE and other causes. Results: A reduction of the inaccuracy range from 20% to 15% would translate into a 25.5% reduction of SHE. The incremental cost per SHE avoided would be -2,795€ . The reduction in SHE would lead to cost savings of 135€ per T2DM insulin-treated patient and year. Considering there are 379,728 T2DM insulin-treated patients in Spain, the total cost savings would exceed 51€ million, meaning 0.9% of total Spanish diabetes expenditure and 0.07% of total Spanish health care expenditure. ConClusions: Self-monitoring blood glucose is a key component of diabetes management as it is often used in clinical decision making. It is therefore critical that these devices are accurate and precise. The results of this study might encourage the conversion of all patients using non ISO compliant meters to ISO compliant meters in the European Union, where ISO 15197:2013 will become mandatory in May 2016. It might also enhance stricter standards in countries where these requirements will not be mandatory.
PMD59 hexaMinolevulinaTe Blue-lighT flexiBle cysToscoPy in aDDiTion To sTanDarD WhiTe-lighT cysToscoPy in The folloW-uP of non-Muscle invasive BlaDDer cancer: cosT-consequences During ouTPaTienT surveillance in sWeDen
Dansk V 1 , Malmström P 2 , Bläckberg M 3 , Malmenäs M 1 1 PAREXEL, Stockholm, Sweden, 2 Uppsala University, Uppsala, Sweden, 3 Helsingborg Hospital, Helsingborg, Sweden objeCtives: Bladder cancer (BC) can be life-long and requires intensive and routine monitoring and treatment, which makes it costly and impacts on patients' health perception. Hexaminolevulinate is a photosensitizing agent selectively absorbed by cancer cells which light up in red when illuminated with blue light, approved for improved detection and management of BC. The objective was to evaluate the costconsequences of using Hexaminolevulinate-guided blue-light flexible-cystoscopy (HBLFC) as an adjunctive to white-light flexible-cystoscopy (WLFC), compared with WLFC alone, in the detection of non-muscle invasive BC (NMIBC) one year after diagnosis and recurrence. Methods: A cost-consequence model using a combination of a decision tree and Markov cohort state transition model structure was developed using a Swedish setting, Swedish guidelines and a hospital perspective. 231 patients were followed in an outpatient setting after diagnosed with NMIBC and successfully treated with an initial transurethral resection of bladder tumour (TURBT).The 231 patients were distributed across all risk groups. The model captured costs (2014 SEK) of surveillance and treatment of recurrence and progression over a 5-year period using 3-month-cycles. Results: The total cost over five years was marginally higher, 1.6%, for HBLFC (SEK 14,033,864) compared to WLFC (SEK 13,815,155) although cost-saving from year 2. HBLFC resulted in reduced resource demand versus the comparator (TURBTs: 121.4 vs 126.1; cystectomies: 56.3 vs 58.8; operating room [OR] time [hours]: 428.9 vs 447.4; bed days: 18.7 vs 19.5). High-risk patients represented the largest share of the costs but also the main benefits in clinical outcomes. ConClusions: HBLFC was cost neutral over 5 years and reduced the number of bed days and OR time compared to WLFC alone, resulting mainly from fewer TURBTs and cystectomies. The greatest overall benefits were seen among high-risk patients, but other risk-groups are likely to benefit as well. Future model development will include quality-of-life data.
PMD60 a Decision Tree MoDel To evaluaTe The cosTs anD consequences of using Dual anTiBioTic Bone ceMenT versus single anTiBioTic Bone ceMenT in hiP heMiarThroPlasTy
Griffiths M 1 , Slater D 1 , Hanstein T 2 1 Costello Medical Consulting Ltd, Cambridge, UK, 2 Heraeus Medical GmbH, Wehrheim, Germany objeCtives: The use of antibiotic-laden bone cements in surgical operations of the hip aims to help prevent surgical site infections (SSIs) and avoid their negative consequences. The objective of this study was to evaluate the costs and consequences for the NHS in England and Wales associated with the use of a dual antibiotic cement (COPAL® G+C) compared to a single antibiotic cement (PALACOS® R+G) in the treatment of fractured neck of femur with hemiarthroplasty. Methods: A de novo decision tree model was developed, incorporating relevant clinical events of 30-day mortality, superficial and deep SSIs, and revision procedures, over a 1 year time horizon. Probabilities were informed by published literature and results of a key randomised controlled trial comparing the two interventions. Costs were sourced by applying the meta-analytic results to U.S. lengths of stay, costs, and practice patterns. We estimated the annual ARI visit rate for the one million member cohort, by setting (inpatient, ICU, outpatient) and ARI diagnosis. Results: In the inpatient setting, the costs of procalcitonin -guided care for the one million member cohort was $2,083,545, compared to $2,780,322, resulting in net savings of nearly $700,000 to the IDN for the year 2014. The ICU and outpatient setting, the savings to the IDN were $73,326 and $5,329,824, respectively, summing up to overall net savings of $6,099,927 for the cohort. Results were robust for all ARI diagnoses. For the whole U.S. insured population, procalcitonin-guided care would result in $1.6 billion in savings annually. ConClusions: Our results show substantial savings associated with procalcitonin protocols of ARI across common U.S. treatment settings. These results are robust to changes in key parameters, and the savings can be achieved without any negative impact on treatment outcomes.
PMD55 a MicrocosTing sTuDy of raDiaTion TheraPy in localizeD ProsTaTe cancer PaTienTs in a hungarian TerTiary oncology cenTer
Zemplényi A 1 , Kaló Z 2 , Boncz I 1 , Endrei D 1 , Mangel L 1 1 University of Pécs, Pécs, Hungary, 2 Eötvös Loránd University (ELTE), Founder & CEO, Syreon Research Institute, Budapest, Hungary objeCtives: The purpose of our analysis was to determine the costs of the conventional three-dimensional radiation therapy (3DCRT) and the normal and hypofractionated intensity-modulated radiation therapy (IMRT and HF-IMRT) for the treatment of localized prostate cancer, and to compare the treatment costs with the reimbursement fees. Methods: The cost-analysis was performed with microcosting method based on the data of a Hungarian oncology center from the perspective of the health care provider. We estimated the resource use in each phase of the radiation therapy process through face-to-face interviews with radiation oncologists, radiation therapists and physicists. The average positioning and treatment delivery time were assessed from the data of 100 fractions delivered in 20 patients. A unit cost for each cost component was calculated based on the actual costs retrieved from the accounting system of the oncology center. We assumed the irradiation scheme to use a total of 38 fractions in the 3DCRT and IMRT, and 25 fractions in the hypofractionated scheme. Capital costs were taken into consideration in the cost calculation. Costs were converted to EUR by applying actual exchange rates (1 EUR = 309 HUF). Results: Based on our calculations the expected mean cost of patients undergoing 3DCRT, IMRT and HF-IMRT were 2,105 EUR, 3,066 EUR and 2,244 EUR respectively. The current reimbursement fee for 38 and 25 fractions are 3,513 EUR and 2,635 EUR respectively. ConClusions: Although IMRT and HF-IMRT has already been proven to be cost-effective compared to 3DCRT, the current reimbursement fees do not encourage healthcare providers to use the more effective therapy techniques. The revision of intervention codes, DRGs and cost-weights in terms of radiation therapies for prostate cancer is desirable in order to resolve this anomaly.
PMD56 analysis of cosTs for Diagnosis anD DifferenTial Diagnosis of PaTienTs WiTh PossiBle TeMPoroManDiBular DisorDers in ukrane
Telishevska O, Makeyev V. , Telishevska U. V. , Shybinskyy L, Piniazhko O Danylo Halytsky Lviv National Medical University, Lviv, Ukraine objeCtives: According to a number of publications frequency of complaints on temporomandibular joints (TMJ) ranges from 27 to 76% and is on a third place in modern dentistry after other dental diseases such as caries and its complications and periodontal pathology. The necessity of high-quality, relevant and available for patient diagnosis is increasing. To evaluate and compare the costs for diagnosis of patients with possible TMD from the payer's perspective in the reform period of health care system and implementation of health insurance in Ukraine. Methods: For the diagnosis of TMJ violations such alternative methods may be used: orthopantomography (OPG), zonography (ZG), ultrasonography (USG), 3D computed tomography (3D CT) and magnetic resonance imaging (MRI). From December 2013 to June 2015 122 patients with suspected TMD at Prosthetic Dentistry Department Danylo Halytsky Lviv National Medical University were examined. Results: The above mentioned methods singly and in combination were used for diagnosis. The costs of examination according to the average data in private and public clinics in Lviv are: OPG -5-7 € ; ZG -5-7€ , USG -7-9 € , 3D CT -18-30 € , MRI -30-50 € . Resulting 62 OPG, 22 ZG, 54 USG, 20 3D CT and 2 MRI were conducted. Consequently, OPG, ZG and USG are available for most patients, less available is 3D CT. MRI is the most limited method. ConClusions: Such diagnostic methods as OPG, ZG and USG are the most available for patients. They are informative, have no excessive radiation exposure and allow them to re-apply if the forward observation is necessary. In some cases the 3D CT method should be combined with USG, so that complex has a higher cost. MRI is the "gold" standard for diagnosis, but the high cost and features of study may limit its usage.
PMD57 finDing The oPTiMal screening PrograM for unknoWn aTrial fiBrillaTion using siMulaTion MoDels
Aronsson M, Levin L Linköping University, Linköping, Sweden objeCtives: The primary objective of this study was to use computer simulations to determine the optimal age for initiation of screening for atrial fibrillation and to evaluate if repeated screening is of additional value. Methods: This analysis was based on a decision-analytic simulation model. More than one billion different designs of screening programs for unknown atrial fibrillation were simulated and analyzed. Widely accepted decision rules for mutually exclusive programs were used to identify optimal designs for screening for unknown atrial fibrillation. Results: Costs and effects generated by the 1,073,741,824 possible screening designs was calculated and compared. Of all possible programs, 1,073,741,818 designs were ruled out from the analysis based on dominance, extended dominance or the fact that the program design had an incremental cost of over € 100 000 per gained QALY. The
